RT Journal Article
SR Electronic
T1 One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.08.21264715
DO 10.1101/2021.10.08.21264715
A1 Inna V Dolzhikova
A1 Vladimir A Gushchin
A1 Dmitry V Shcheblyakov
A1 Alexander N. Tsybin
A1 Alexey M Shchetinin
A1 Andrey A Pochtovyi
A1 Andrey B Komissarov
A1 Denis A. Kleymenov
A1 Nadezhda A Kuznetsova
A1 Amir I Tukhvatulin
A1 Olga V Zubkova
A1 Alina S Dzharullaeva
A1 Anna V Kovyrshina
A1 Nadezhda L Lubenets
A1 Daria M Grousova
A1 Alina S Erokhova
A1 Fatima M Izhaeva
A1 Olga Popova
A1 Tatiana A Ozharovskaya
A1 Alexander S Semikhin
A1 Elizaveta A Tokarskaya
A1 Maksim M Shmarov
A1 Natalia A Nikitenko
A1 Elena V Shidlovskaya
A1 Evgeniia N. Bykonia
A1 Elena P. Mazunina
A1 Elizaveta V Divisenko
A1 Lyudmila A Vasilchenko
A1 Liubov I. Popova
A1 Daria M Danilenko
A1 Dmitry A Lioznov
A1 Artem P Tkachuk
A1 Sergei V Borisevich
A1 Boris S Naroditsky
A1 Denis Y Logunov
A1 Alexander L Gintsburg
YR 2021
UL http://medrxiv.org/content/early/2021/10/14/2021.10.08.21264715.abstract
AB Objectives Vaccination remains the most effective response to the COVID-19 pandemic. Most vaccines use two-dose regimens. In turn, single-dose vaccines also have high potential, since, on the one hand, they simplify the vaccination program, make it more accessible and convenient for more people around the world, and on the other hand, they are better suited for subsequent revaccination. However, there is not enough data on the effectiveness of single-dose vaccine variants against new genetic lines to assess their current potential. It is not clear how much a single dose of immunization protects against the globally dominant delta variant. In this work, we investigated the effectiveness of a single dose vaccine (Sputnik Light, the first component of Sputnik V vaccine) against the Delta variant in Moscow.Methods To assess the effectiveness of one dose of viral vector vaccine based on rAd26 against the delta variant in Moscow, we used data from the Moscow registries of vaccination against COVID-19 and the incidence of COVID-19. The availability of data on the number of seropositive residents of Moscow made it possible to consider the size of the immune layer formed because of a previous COVID-19 disease or vaccination. To calculate the effectiveness, the proportion of COVID-19 cases among those vaccinated with a single dose and the proportion of cases among those who were not vaccinated in July 2021.Results Our data indicate that throughout July 2021, the dominant variant of the coronavirus at the level of 99.5% in Moscow was the SARS-CoV-2 delta variant and its subsidiary lines. Considering the immune layer of 46% allowed us to calculate the effectiveness of a one-shot vaccine against the delta variant in Moscow during the first three months after vaccination at the level of 69.85% (95% confidence interval [CI], 64.08 to 74.70). In the 18-29-year-old group, the overall vaccine efficacy against the delta variant was 88.61%, in the 18-59 group - 75.28%. Sputnik Light demonstrates higher efficacy against Delta variant than many two-shot vaccines.Conclusion The results indicate a high efficacy of a single immunization first component of Sputnik V vaccine against delta variant among young and middle-aged people, at least during the first 3 months after receiving the one-shot vaccine.Competing Interest StatementIVD, DVS, AIT, OVZ, ASD, DMG, ASE, OP, TAO, ASS, EAT, NAN, SVB, BSN, DYL and ALG report patents for a Sputnik V immunobiological expression vector, pharmaceutical agent, and its method of use to prevent COVID-19. All other authors declare no competing interests.Funding StatementThe study was funded by Ministry of Health of Russia, Moscow Healthcare Department and Russian Direct Investment Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was submitted to the Local Ethics Committee of the Gamaleya Center. The committee concluded that the study did not use identifiable biological samples and did not provide any confidential data. Consequently, according to the Local Ethics Committee rules and national regulations, this project does not require ethical approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript